Oct 21 (Reuters) - Inovio Pharmaceuticals Inc :
* INOVIO ANNOUNCES NEW DATA AT SCIENTIFIC CONFERENCES FOR LEAD CANDIDATE, INO-3107, AS A POTENTIAL TREATMENT FOR RRP
* INOVIO PHARMACEUTICALS INC - INO-3107 WELL TOLERATED, 81% OF PATIENTS REQUIRED FEWER SURGERIES POST-TREATMENT
* INOVIO PHARMACEUTICALS INC - 81% OF PATIENTS EXPERIENCED FEWER SURGICAL INTERVENTIONS POST-TREATMENT WITH INO-3107
* INOVIO PHARMACEUTICALS INC - INO-3107 WELL TOLERATED, MOST FREQUENT AES WERE INJECTION SITE PAIN AND FATIGUE
Source text for Eikon: Further company coverage:
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。